| Nicole Krishna Devine, CNM | |
|
3440 Burnet Ave, Suite 120, Cincinnati, OH 45229-2833 | |
| (513) 751-5900 | |
| (513) 487-4590 |
| Full Name | Nicole Krishna Devine |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 27 Years |
| Location | 3440 Burnet Ave, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336360676 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | NM-08389 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bethesda North | Cincinnati, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trihealth H Llc | 1850570458 | 668 |
News Archive
Chloride plays a key role in the formation of the basement membrane, a suprastructure on the outside of cells that undergirds and guides the function of most of the tissues of the body.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.
Allos Therapeutics, Inc. today announced the presentation of favorable survival data from the Company's international, randomized Phase 2b investigational study of FOLOTYN relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population.
Research published by the University of Helsinki, Finland, indicates that cytostatic and radiation therapies administered before stem cell transplantation often damage children's permanent teeth.
› Verified 7 days ago
| Entity Name | Trihealth G Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295862944 PECOS PAC ID: 0749222651 Enrollment ID: O20050601000358 |
News Archive
Chloride plays a key role in the formation of the basement membrane, a suprastructure on the outside of cells that undergirds and guides the function of most of the tissues of the body.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.
Allos Therapeutics, Inc. today announced the presentation of favorable survival data from the Company's international, randomized Phase 2b investigational study of FOLOTYN relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population.
Research published by the University of Helsinki, Finland, indicates that cytostatic and radiation therapies administered before stem cell transplantation often damage children's permanent teeth.
› Verified 7 days ago
| Entity Name | Trihealth H Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811215742 PECOS PAC ID: 1850570458 Enrollment ID: O20110128000356 |
News Archive
Chloride plays a key role in the formation of the basement membrane, a suprastructure on the outside of cells that undergirds and guides the function of most of the tissues of the body.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.
Allos Therapeutics, Inc. today announced the presentation of favorable survival data from the Company's international, randomized Phase 2b investigational study of FOLOTYN relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population.
Research published by the University of Helsinki, Finland, indicates that cytostatic and radiation therapies administered before stem cell transplantation often damage children's permanent teeth.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Krishna Devine, CNM 4685 Forest Ave, Ste C, Cincinnati, OH 45212-3359 Ph: (513) 569-6117 | Nicole Krishna Devine, CNM 3440 Burnet Ave, Suite 120, Cincinnati, OH 45229-2833 Ph: (513) 751-5900 |
News Archive
Chloride plays a key role in the formation of the basement membrane, a suprastructure on the outside of cells that undergirds and guides the function of most of the tissues of the body.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.
Allos Therapeutics, Inc. today announced the presentation of favorable survival data from the Company's international, randomized Phase 2b investigational study of FOLOTYN relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population.
Research published by the University of Helsinki, Finland, indicates that cytostatic and radiation therapies administered before stem cell transplantation often damage children's permanent teeth.
› Verified 7 days ago
Mrs. Meryll Guillory Thomas-langford, APRN.CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 3219 Clifton Ave Ste 210, Cincinnati, OH 45220 Phone: 513-751-5900 | |
Leah A. Terhune, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 4244 Hamilton Ave, Cincinnati, OH 45223 Phone: 513-681-4900 Fax: 513-853-8432 | |
Donna O Patno, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3333 Burnet Ave, Cincinnati, OH 45229 Phone: 513-636-9608 | |
Ms. Nancy Lynn Baron, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 3440 Burnet Ave, Ste. 120, Cincinnati, OH 45229 Phone: 513-751-5900 Fax: 513-487-4590 | |
Deena Jo Parsons, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 3440 Burnet Ave, Suite 120, Cincinnati, OH 45229 Phone: 513-751-5900 Fax: 513-487-4590 | |
Mrs. Andrea Chipps, CNM, APRN Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 3440 Burnet Ave, Cincinnati, OH 45229 Phone: 513-751-5900 | |
Sapphira Champange Pranger, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3219 Clifton Ave Ste 210, Cincinnati, OH 45220 Phone: 513-751-5900 Fax: 513-487-4590 |